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Just over 25 years ago, an 8-year-old girl with acute
myelogenous leukemia (AML) who coincidentally
had sickle cell disease (SCD) underwent a successful
matched sibling donor bone marrow transplant
(BMT) for her leukemia from her otherwise healthy
brother who had sickle cell trait. This was the first
time that BMT had been shown to ‘‘reverse’’ SCD
even though SCD was not the indication for BMT
[1]. A few years later, Lucarelli et al. [2] published re-
sults of BMT in children with b-thalassemia major,
demonstrating 87% thalassemia-free survival in pa-
tients with Class 1 thalassemia. A subsequent national
trial of BMT for SCD using matched sibling donors
initiated in 1991 showed promising results with 55 of
59 recipients surviving, 50 of them free of SCD [3].
Despite these promising outcomes, to date, only a
few hundred children have undergone BMT for SCD
despite the fact that there may potentially be thousands
of eligible children with severe SCD and available allo-
geneic donors. There are many factors that contribute
to this significant disparity between numbers of trans-
plants and eligible patients.
Although children with SCD demonstrate a vari-
able phenotype with only 7% to 20% having the severe
phenotype, the progressive organ damage that occurs
in many patients contributes to a poor quality of life,
rapid decline in survival during early adulthood, and1Children’s National Medical Center, Washington, DC;
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major, on the other hand, has a much less variable clin-
ical course, with most patients requiring regular blood
transfusions starting in late infancy or early childhood.
Allogeneic BMT from either a matched sibling or un-
related donor has become the ‘‘standard of care’’ for
b-thalassemia major. This is also true of other in-
herited diseases of the lymphohematopoietic system
such as Wiskott-Aldrich syndrome where early BMT
soon after diagnosis is now recommended when
a well-matched allogeneic donor is available. Yet,
among patients with SCDwho end up on chronic tran-
sufusion therapy because of severe SCD-related mor-
bidity, many who have matched sibling donors do
not undergo BMT. Whereas unrelated donor BMT
has been carried out for thalassemia and WAS since
the 1990s, it has been considered experimental for chil-
dren with SCD and is only recently being investigated
in a clinical trial setting. It is worth exploring why the
application of this ‘‘curative’’ therapeutic approach to
SCD is different than in thalassemia and perhaps con-
sidering a paradigm shift.
Based on the experience with children with in-
herited primary immune deficiency diseases who have
now been followed for almost 4 decades after BMT,
there is no reason to believe that patients with SCD
who undergo BMT will not derive a long-lasting
benefit. Mounting evidence points to resolution of
SCD-related symptomatology and stabilization or im-
provement of organ function after successful BMT for
SCD. Long-term complications such as sterility and
a slightly increased risk of cancer aside, BMT survivors
should be ‘‘cured’’ of their underlying hemoglobinopa-
thy. The medical literature is rife with articles that talk
of cure of thalassemia by BMT, yet this term is infre-
quently used for SCD and BMT. Most contemporary
informational and educational brochures on SCD
rarely mention BMT as a therapeutic option. A recent
publication from the Centers for Disease Control and
Prevention states ‘‘Symptomatic treatments exist, but
there is no cure for SCD.’’ The parents alert brochure
for those whose children have screened positive for
SCD from the Texas Department of State Health Ser-
vices states that ‘‘there is no cure for SCD but with
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almost all the deaths in young children can be pre-
vented.’’ The guidelines for the management of SCD
complications for healthcare providers from the SCD
Care Consortium (supported by the Texas DOH),
however, states: ‘‘Successful allogeneic hematopoietic
stem cell transplantation provides a hematologic cure
for SCD.’’ The FAQ section on the Website of the
SCD Association of America, Inc. (a leading commu-
nity SCD organization) makes no mention of BMT,
and categorically states that there is no universal cure
for SCD,but that research in gene therapy, the ultimate
universal cure, is underway. This dichotomy between
the information provided to healthcare teams on the
one hand and to the patients, parents, and the lay public
on the other lends credence to the perception that
medical paternalism has long been practiced in the
management of this disease.
Surveys of adults with SCD and of parents of chil-
dren with SCD have shown that there is no agreement
between the recommendations of healthcare providers
and the risks that patients and parents are willing to ac-
cept to obtain a ‘‘cure’’ for their disease. In view of the
substantial patient interest in curative therapy, the au-
thors recommended that education about and consul-
tation for BMT in patients with SCD be encouraged
[4,5]. During the conduct of the national matched
sibling donor trial for SCD, Walters et al. [6] looked
into the barriers to BMT. Although the lack of an
HLA-identical sib donor was the major barrier,
physician refusal was more frequently encountered
than parent refusal. The increasing availability of
well-matched unrelated donors should alleviate the
most significant barrier to BMT for eligible patients
with severe SCD. With the ever increasing exposure
to media and wide availability of access to the Internet,
more and more patients and families are empowering
themselves with scientific information in order to re-
ject medical paternalism. Patient and parent education
and empowerment and an honest discussion of risks,
BMT outcome uncertainties and benefits of BMT
should be fostered.
A report by Smith et al. [7] details the important
gaps that exist in the equity of funds (both federal and
private sector) allocated to research and in the imple-
mentation of advances in clinical care for sickle cell dis-
ease compared to cystic fibrosis. Although mortality in
children with SCD has significantly decreased over the
past 4 decades, the widespread adoption of best clinical
practices and quality improvement efforts have lagged
behind. This is especially true for adults with SCD
for whom removing barriers of access to health insur-
ance and implementation of quality comprehensive
care can improve quality of life and survival.
In order that parents of children with SCD are
made aware of not only the uncertain prognosis for
their child but all potential therapeutic options at thetime of diagnosis, it is important to include accurate
information detailing the role of BMT, its indications
and potential toxicities, in parent brochures and edu-
cation. This is an important consideration in the para-
digm shift. As physicians, ourHippocratic oath tells us:
Primum non nocere, or first, do no harm. Does this only
mean not considering a therapeutic option that may be
potentially fatal? Are we perhaps not doing harm by
not offering a potentially curative therapy and subject-
ing the patient to a lifetime of morbidity, decreasing
neurocognitive function, poor quality of life and the
prospect of premature lethality?
The ethical challenges of offering a potentially cu-
rative therapeutic option with a small but finite risk of
treatment-related mortality in a disease where the pa-
tient and family are not faced with the prospect of mor-
tality in the short term (unlike refractory leukemias or
severe aplastic anemia) are clearly difficult and fraught
with controversy. Both the patient and family and the
healthcare team have to be willing to accept this mor-
tality risk in exchange for potential cure. This ethical
dilemma is explored in more detail below.ETHICAL CHALLENGES IN TRANSPLANT
DECISIONS FORNONMALIGNANTDISEASES
John D. Lantos, MD, Doug Myers, MD
SCD and thalassemia are 2 nonlethal conditions in
which a bone marrow transplantation cures the dis-
ease. The 2 offer interesting contrasts that shed light
on the ethical paradigms that govern the use of BMT
for nonlethal conditions. Both b-thalassemia major
and SCD can be reliably diagnosed. The clinical
course in SCD, however, can vary widely. Some
children have virtually no sequelae or complications
from their disease. Others are debilitated by strokes,
acute chest syndrome, or recurrent vaso-occlusive cri-
ses. Life expectancy is lower in b-thalassemia than in
SCD disease and is more heavily dependent upon the
availability of hypertransfusion and chelation.
The severity of the disease and the lack of variation
in clinical course make the decision to transplant chil-
dren with thalassemia less controversial, particularly if
they have a sibling who is an excellent match. By con-
trast, the variable course in SCD makes it crucial to
rely upon prognostic factors other than the diagnosis
itself. Children with SCD do not become eligible for
BMT unless they have other morbidity. Even then,
the decision is complicated. To offer BMT for SCD,
doctors must understand that they are offering a treat-
ment that has a chance of significantly shortening the
patient’s life.
The ethical challenges of evaluating such a pro-
posed therapy are daunting. SCD is a chronic disease
that is usually not immediately life threatening. Today,
in the United States, most patients with SCD survive
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morbidity from their disease. The most worrisome
morbidities are from either strokes or from recurrent
vaso-occlusive pain crises. Strokes can leave people
seriously debilitated. Pain crisis sometimes require
dozens of hospitalization each year with frequent use
of high doses of narcotic analgesics. How does one bal-
ance the risks and burdens of the disease against the
risks of treatment? Who should do the balancing?
One of the interesting features of transplant deci-
sions for patients with SCD is that patients seem will-
ing to take more risk for a chance to cure their disease
than doctors or institutional review boards (IRBs) are
willing to allow them to take. Kodish et al. [8] studied
parents who had children with sickle cell disease, using
standard reference gamble techniques. These tech-
niques present parents with a gradually increasing level
of risk, both for mortality from a transplant and mor-
bidity from graft-versus-host disease (GVHD). A third
of parents were willing to accept a 15% short-term
mortality risk for a chance at cure. Thirteen percent
would accept that plus a 15% risk of GVHD. Many
IRBs consider any risk of death above 5% unaccept-
able. There are no studies of children’s own views,
but 15% of adults with SCD are willing to accept
amortality risk of 35% for a chance at cure. Actual out-
comes, for carefully selected patients, are an overall
mortality rate of about 7% with event-free survival
rates of 85%.
These numbers suggest that we either underesti-
mate the burden of SCD or have standards of accept-
able risk for patients that are much more cautious
than the standards that they would make for them-
selves. These studies raise questions about patient
autonomy, about professional integrity, about the pos-
sibility of truly informed consent, and about the proper
locus of responsibility for decisions such as this one.
Three factors shape any decision to offer BMT for
a nonlethal condition. First, how bad is the health-
related quality of life for the people with the disease?
Second, are there any prognostic factors that allow
more accurate predictions of the clinical course for in-
dividual patients—that is, if we knew which patients
with SCD were most likely to have debilitating strokes
or vaso-occlusive crises, we could selectively transplant
them rather than others. Finally, we must consider the
likelihood of success or failure of the transplant and do
so in light of the quality of the match that is available.
These factors then lead to a 2-stage decision process.
First, doctors must decide if they are willing to even of-
fer a transplant. There may be situations in which par-
ents or patients want a transplant but in which doctors
feel it is too risky. We know from studies of practice
variation between centers that different groups of
transplanters have different thresholds of risk and
benefit. If doctors are willing to offer a transplant,
then parents and patients must participate in a rigorousprocess of informed consent. This is, after all, a more
elective treatment than some. Meticulous attention
to patient understanding is crucial. It may take time,
but, given the nature of the disease and the treatment,
there is time.
The informed consent process needs to deal with
some issues that go beyond merely the statistics on
prognosis with and without transplant, mortality risks,
or the risks (and nature of) GVHD. One of the issues
concerns timing of the transplant.Generally, outcomes
are better when transplants are done earlier in life.
Generally, prognostic accuracy is worse early in life.
A program of early transplantation will result in
the transplantation of some children who may not
have needed it, but will likely lead to better outcomes
overall for the population of transplanted children. A
related issue concerns preservation of fertility. Gener-
ally, transplantation leads to infertility. For BMT re-
cipients who have gone through puberty, fertility can
be preserved by harvesting sperm or ova for later use
in an in vitro fertilization setting. Transplantation
prior to puberty does not allow this option. This, too,
must be factored into the decision, along with other
variables that favor either early or late transplantation.
In this transplantation situation, as in others, the
donor faces a set of challenges that may be underesti-
mated or ignored by the transplant team. Donation is
not without risk, even though the risk is relatively
low. More importantly, donors have well-described
psychologic problems. They may feel used, neglected,
or, if the transplant fails, guilt-ridden. A recent survey
of HCT centers in the United States revealed that
transplantation physicians were involved or potentially
involved in overlapping care of the hematopoietic cell
transplant (HCT) donor and the recipient in.70% of
centers with similar practices for both adult or pediat-
ric donors and recipients [9]. A policy statement from
the committee on bioethics of the American Academy
of Pediatrics recommends that specific criteria be met
before minors can serve as stem cell donors [10]. Many
pediatric programs now have donor advocacy pro-
grams that are specifically designed to attend to the
physical and psychologic needs of the donor. How-
ever, it is not clear whether the AAP recommendations
have gained wide acceptance among the HCT com-
munity. More studies need to be done to better under-
stand the experience of donors in nontraditional
transplantation situations.
Another issue that has recently come to the fore-
front is the question ofwhether it is ethical to give gran-
ulocyte colony stimulating factor (G-CSF) prior to
a bone marrow harvest to sibling donors who are mi-
nors. The federal government was asked by the COG
to review and comment on this issue during the ap-
proval process for a phase III, multi-institutional,
randomized trial of G-CSF stimulated bone marrow
versus conventional bone marrow as a stem cell source
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the FDA’s Pediatric Ethics Subcommittee first
determined that G-CSF administration involved
more than a minor increase over minimal risk, with
no benefit to the donor. However, they also felt that
the research presented ‘‘a reasonable opportunity to
further the understanding, prevention, or alleviation
of a serious problem affecting the health or welfare of
children.’’ Therefore, they felt, ‘‘the research can be
conducted in accord with sound ethical principles
(with 1 dissenting vote), assuming that provisions
were made to strengthen protection of the donors.
These extra protections included additional donor ex-
clusion criteria, mandating a donor advocate, mandat-
ing stricter criteria for the data safety monitoring
board, and giving preference to older donors over
younger ones [11].THE ETHICS OF CREATING A STEM CELL
DONOR
Jeffrey P. Kahn, PhD
In the years after preimplantation genetic diagno-
sis (PGD) was developed and first introduced, its use
had been restricted to avoiding disease in future chil-
dren for couples at risk of passing on genetic disease.
In cases where PGD is used to select HLA-matched
in vitro fertilized (IVF) embryos for the purpose of cre-
ating a hematopoetic stem cell donor, however, the
distinction between testing for a disease and testing
for some other, nondisease trait was ignored. The sec-
ond stage, however, crossed the line between avoiding
genetic disease and selecting for some nondisease trait
by testing the remaining embryos for HLA status. Fur-
ther complicating the analysis, the selection of HLA
status is not to benefit the child that would develop
from the tested embryo, but to ensure immune com-
patibility with the future child’s sibling. For some,
the concern about selecting traits for this purpose is
softened by the argument that were it not for the fact
that the child born from the selected embryo was
both disease-negative and HLA-matched to his or
her sibling, the child would not have been born. In
other words, if a couple had selected an embryo only
based on its FA-negative status, in all probability an-
other child would have been born because numerous
disease-negative (but HLA incompatible) embryos
are usually available earlier in the process.Does Motivation Matter?
The concern is that parents could use predictive
genetic testing technologies like PGD for reasons
that serve themselves or their existing children but
have very little to do with the interests of the future
child. Given the wide range of reasons andmotivationsfor having children, it is difficult to argue convincingly
that having a child to save the life of an existing sick
child is such a bad parental motivation.
Parents are prevented from abusing or neglecting
their children, with the state stepping in and even re-
moving children from their parents when their health
and safety are threatened.We, unfortunately, can envi-
sion cases in which parents might create children to
serve their own or their other children’s interests in
ways that could violate those limits. More successful
would be efforts to oversee the treatment of the chil-
dren after they are born, and to make sure that an ap-
propriate risk-benefit balance exists when children are
used as donors.The Policy Gap
Using IVF and PGD for the purpose of creating
a stem cell donor relies on a new combination of exist-
ing technologies—creation of embryos by IVF, use of
PGD for selection of traits, and collection and use of
umbilical cord blood for transplant. There are 3 areas
that together point to a policy gap in the oversight of
the new use of these technologies: (1) multiple sites
leading to no locus of overall responsibility, (2) limited
mechanisms for assessing acceptable creation and uses
of human embryos, and (3) limited third-party payer
oversight of the medical technologies involved [12].
First, the experience with these cases (eg, the
Molly Nash case and others) makes clear that whatever
controls we might suggest, the fact that the various
elements of the process can take place at different
sites makes coordinated review and oversight difficult.
In the Nash case, IVF was performed at a clinic in
Denver, PGD in Chicago, and the cord blood trans-
plant in Minneapolis [13]. Rules or oversight dictated
by the IVF clinic have little impact on behavior at
the PGD clinic or in the transplant unit, and vice
versa. The upshot of having multiple sites for the in-
dividual elements is that there is no locus of overall
responsibility for the process, which creates an envi-
ronment in which each of the individuals and institu-
tions involved can make decisions at their own
discretion and then claim that the implications result-
ing from the combination of technologies are out of
their control.
Second, there are few if any mechanisms for assess-
ing the acceptable creation and uses of human em-
bryos, particularly in the medical context. Part of the
policy gap is related to the practice of reproductive
medicine and the creation of human embryos. Repro-
ductive medicine clinics in the United States and
abroad create embryos as part of routine, high-tech
medical care for infertility. Such creation is subject
to little oversight or review. Recent surveys suggest
that in the United States alone there are nearly
400,000 frozen embryos in storage, left over from
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are subject to private contracts with the lab and infer-
tile couples and individuals, but otherwise are subject
to few legal restrictions, if any, on their future use, in-
cluding experimental uses.
In the research context, U.S. policies and practices
for decades have effectively prohibited the use of fed-
eral funds in any research that harms or destroys human
embryos. This funding limitation has a complex policy
history that has been well-documented elsewhere [15],
and is a reflection of the political andmoral controversy
surrounding abortion. However, in the absence of fed-
eral research funding, funding-related rules or restric-
tions do not exist: embryos can be created, destroyed,
experimented upon, and used for any purpose so long
as no federal dollars are used. In addition, much of
the work that takes place in reproductive clinics typi-
cally has not been classified as research, but rather as in-
novative clinical practice, an area that in law and policy
historically has been left to the discretion of individuals
and institutional policies. Indeed, as numerous others
have pointed out [15-17], reproductive medicine is
among the least regulated or controlled areas of
medicine.
A third component of the policy gap is a product of
the limited third-party payer oversight of reproductive
medicine. Reproductive medicine long has enjoyed
a market-oriented approach to oversight, in part be-
cause such a large proportion of the costs of reproduc-
tive medicine services are born by patients directly and
not by third-party payers. Because insurers pay so few
of the costs of IVF and other reproductive medicine
services, they have little say over the appropriate uses
of the technologies involved. Instead, market forces
decide the restrictions, if any, that should exist. Like-
wise, any attempts at self-regulation by reproductive
medicine specialists are more influenced by patient de-
mand and willingness to pay than by any criteria that
the profession might deem appropriate.
To summarize, efforts to control or oversee the cre-
ation of immune-matched stem cell donors falls neatly
into a policy gap, a gap that could easily occur again in
other overlapping technology uses. This policy gap
stems from the combination ofmultiple sites of respon-
sibility and lack of any locus of responsibility for the
overall process; the limited oversight of IVF and other
reproductivemedicine services owing in part to the em-
bryo research ban; and the market-driven nature of re-
productive medicine. This gap has implications not
only for the use of the individual technologies involved,
but also for how they might be used in combination in
the future.
Policy Recommendations
What can be done to improve the policy environ-
ment for intervention and/or oversight in the creationof stem cell donors? (1) Move the debate from the
clinic to the public policy arena, (2) avoid reactive pol-
icymaking, (3) create local mechanisms for review of
and advice on controversial uses of biomedical tech-
nologies, and (4) consider lessons from others, partic-
ularly oversight efforts in other countries.ACKNOWLEDGMENTS
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